Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use

Journal of Psychopharmacology

Volumn 24, Issue 4, 2010, Pages 623-624

  Kuloglu, M ^a   Caykoylu, A ^a   Ekinci, O ^a   Bayindirli, D ^a   Vural, G ^a   Deniz, O ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; REBOXETINE;

ADULT; AKATHISIA; CASE REPORT; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; ELECTROENCEPHALOGRAM; HUMAN; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PARKINSON DISEASE, SECONDARY; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77950406992     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108099962     Document Type: Letter

References (15)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed, Text Revision. Washington, DC: American Psychiatric Association.
2. Caley, F., Friedman, JH (1992) Does fluoxetine exacerbate Parkinsons disease ? J Clin Psychiatry 53: 278-282.
3. Detweiler, MB, Harpold, GJ (2002) Bupropion induced acute dystonia. Ann Pharmacother 36: 251-254.
4. Goldberg, RJ (1998) Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Fam Med 7: 78-84.
5. Hajós, M., Fleishaker, JC, Filipiak-Reisner, JK, Brown, MT, Wong, EH (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10: 23-44.
6. Hamilton, M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
7. Hedenmalm, K., Güzey, C., Dahl, ML, Yue, QY, Spigset, O. (2006) Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 26: 192-197.
8. Jimenez, FJ, Molina, AJ (2000) Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors. CNS Drugs 14: 367-379.
9. Lu, R., Hurley, AD, Gourley, M. (2002) Dystonia induced by mirtazapine. J Clin Psychiatry 63: 452-453.
10. Ozalp, E., Soygur, H., Cankurtaran, ES, Turhan, L., Cekic, T., Akarsu, ES, et al. (2006) Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. Prog Neuropsychopharmacol Biol Psychiatry 30: 1337-1339.
11. Pintor, L., Baillès, E., Valldeoriola, F., Tolosa, E., Martí, MJ, de Pablo, J. (2006) Response to 4-month treatment with reboxetine in Parkinsons disease patients with a major depressive episode. Gen Hosp Psychiatry 28: 59-64.
12. Schillevoort, I., van Puijenbroek, EP, de Boer, A. (2002) Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 17: 75-79.
13. Simpson, G., Angus, J. (1970) Drug induced extrapyramidal disorders. Acta Psychiatr Scand 45: 11-19.
14. Tanum, L. (2000) Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand 402: 37-40. (Pubitemid 30395386)
15. Vaswani, M., Linda, FK, Ramesh, S. (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102. (Pubitemid 36131110)